Anagrelide, a selective thrombocytopenic agent

American Journal of Health-System Pharmacy

Volumn 55, Issue 19, 1998, Pages 1979-1986

  Oertel, Maryann D ^a   Frazier, Jerry ^b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b University HealthSystem Consortium   (United States)

Author keywords

Anagrelide hydrochloride; Costs; Dosage; Drug interactions; Mechanism of action; Pharmacokinetics; Thrombocytosis; Toxicity

Indexed keywords

ANAGRELIDE; HYDROXYUREA;

ABDOMINAL PAIN; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; EDEMA; HEADACHE; HEART PALPITATION; HUMAN; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; ORAL DRUG ADMINISTRATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT; THROMBOCYTHEMIA;

EID: 0032190424     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.19.1979     Document Type: Review

References (24)

1. Mazur EM, Rosmarin AG, Sohl PA et al. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood. 1992; 798:1931-7.
2. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol. 1997; 34(1):51-4.
3. Broudy VC. Hematology. The polycythemias. In: Dale DC, Federman DD, eds. Scientific American medicine. New York: Scientific American; 1996:1-12.
4. Schrier SL, Leung LLK. Disorders of hemostasis and coagulation. In: Dale DC, Federman DD, eds. Scientific American medicine. New York: Scientific American; 1996:31-3.
5. Spencer CM, Brogden RN. Anagrelide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs. 1994; 476:809-22.
6. Frenkel EP. Southwestern Internal Medicine Conference: the clinical spectrum of thrombocytosis and thrombocythemia. Am J Med Sci. 1991; 3011:69-80.
7. Murphy S, Peterson P, Iland H et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997; 34(1):29-39.
8. Barbui T, Finazzi G, Dupuy E et al. Treatment strategies in essential thrombocythemia: a critical appraisal of various experiences in different centers. Leuk Lymphoma. 1996; 22(suppl 1):149-60.
9. Van Genderen PJJ, Michiels JJ. Primary thrombocythemia: diagnosis, clinical manifestations and management. Ann Hematol. 1993; 67:57-62.
10. Cortelazzo S, Viero P, Finazzi G et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990; 8:556-62.
11. Fruchtman SM, Mack K, Kaplan ME et al. From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997; 34(1):17-23.
12. Schrier SL. Hematology. The leukemias and the myeloproliferative disorders. In: Dale DC, Federman DD, eds. Scientific American medicine. New York: Scientific American; 1996:5-10.
13. Balduini CL, Bertolino G, Noris P et al. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica. 1992; 77:40-3.
14. Agrylin package insert. Eatontown, NJ: Roberts Pharmaceutical Corp.; 1997.
15. Silverstein MN, Petitt RM, Solberg LA et al. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med. 1988; 318: 1292-4.
16. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med. 1992; 92:69-78.
17. Silverstein MN. Anagrelide in myeloproliferative disorders. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia vera and the myeloproliferative disorders. Philadelphia: WB Saunders; 1995:329-36.
18. Gaver RC, Deeb G, Pittman KA et al. Disposition of anagrelide, an inhibitor of platelet aggregation. Clin Pharmacol Ther. 1981; 29:381-6.
19. Mazzucconi MG, De Sanctis V, Chistolini A et al. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica. 1992; 77:315-7.
20. Chintagumpala MM, Kennedy LL, Steuber CP. Treatment of essential thrombocythemia with anagrelide. J Pediatr. 1995; 1273:495-8.
21. Roberts platelet reducer Agrylin achieves 94% response at one study site; 73% complete response rate seen in essential thrombocythemia patients. FDC Rep. 1997(Mar):10-2.
22. Roberts Agrylin launch planned for end of March. FDC Rep. 1997(Mar 24):T&G-1-T&G-2.
23. Hydroxyurea. In: BeDell LS, ed. Physicians genRx. St. Louis: Mosby-Year Book, Inc. 1997:II-1108.
24. Cortelazzo S, Finazzi G, Ruggeri M et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995; 332:1132-6.